New diabetes drug MK-2828 enters early safety testing
NCT ID NCT07089784
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 30 times
Summary
This early-stage study tests a new medicine called MK-2828 in 64 people with type 2 diabetes. The main goal is to check if it is safe and well-tolerated. Researchers will also measure how the drug moves through the body and whether it lowers a marker of inflammation (hsCRP). This is a Phase 1 trial, so it focuses on safety first.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS, TYPE 2 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AMR Clinical ( Site 0003)
Knoxville, Tennessee, 37920, United States
-
AMR Lexington ( Site 0012)
Lexington, Kentucky, 40509, United States
-
Advanced Pharma CR, LLC ( Site 0001)
Miami, Florida, 33147, United States
-
Alliance for Multispecialty Research, LLC ( Site 0013)
Kansas City, Missouri, 64114, United States
-
Bio-Kinetic Clinical Applications, LLC dba QPS-MO ( Site 0009)
Springfield, Missouri, 65802, United States
-
California Clinical Trials Medical Group managed by PAREXEL ( Site 0008)
Glendale, California, 91206, United States
-
ICON Early Phase Services ( Site 0006)
San Antonio, Texas, 78209, United States
-
Jacksonville Center for Clinical Research ( Site 0002)
Jacksonville, Florida, 32216, United States
-
ProSciento Inc. ( Site 0004)
Chula Vista, California, 91911, United States
-
QPS Miami Research Associates ( Site 0005)
South Miami, Florida, 33143, United States
-
Velocity Clinical Research, Hallandale Beach ( Site 0010)
Hallandale, Florida, 33009, United States
Conditions
Explore the condition pages connected to this study.